STOCK TITAN

Armistice Capital (AUTL) reports 17.5M ADS, 6.58% stake in Autolus

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Autolus Therapeutics plc Schedule 13G/A shows Armistice Capital, LLC and Steven Boyd report beneficial ownership of 17,500,000 American Depositary Shares, representing 6.58% of the class as of November 11, 2025. The filing notes 266,141,286 Shares outstanding as of that date and states Armistice Capital exercises shared voting and dispositive power over those shares as investment manager of Armistice Capital Master Fund Ltd.

Positive

  • None.

Negative

  • None.

Insights

Armistice reports a 6.58% stake via shared voting/dispositive power.

Armistice Capital is disclosed as the investment manager for the Master Fund, which directly holds 17,500,000 ADS; Armistice and Steven Boyd report shared voting and dispositive power over those shares. The percentage is calculated using 266,141,286 Shares outstanding as of November 11, 2025.

Holder decisions will determine any future sales; cash-flow treatment and planned transactions are not detailed in the excerpt.

Filing is a joint Schedule 13G/A clarifying beneficial ownership and attribution.

The submission includes a joint filing statement and explains that the Master Fund holds the securities while disclaiming direct beneficial ownership due to the Investment Management Agreement. Steven Boyd is identified as managing member of Armistice Capital and is attributed shared power by virtue of that role.

Filing does not disclose changes in holdings, transactions, or intent; subsequent amendments would be required if holdings change above reporting thresholds.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:02/17/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:02/17/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake does Armistice Capital report in AUTL?

Armistice Capital reports beneficial ownership of 17,500,000 ADS, equal to 6.58% of the class. This percentage is calculated using 266,141,286 Shares outstanding as of November 11, 2025, per the filing.

Who holds and who manages the reported AUTL shares?

The filing states the shares are directly held by Armistice Capital Master Fund Ltd., and Armistice Capital, LLC is the investment manager exercising voting and investment power over those securities on behalf of the Master Fund.

Does Steven Boyd personally own the AUTL shares reported?

Steven Boyd is identified as managing member of Armistice Capital and is deemed to beneficially own the shares through his managerial role. The Master Fund disclaims direct beneficial ownership due to the Investment Management Agreement.

What voting and dispositive powers are disclosed for the AUTL position?

The filing reports 0 sole voting power and 17,500,000 shared voting power; likewise 0 sole dispositive power and 17,500,000 shared dispositive power over the ADS reported.

What baseline share count does the AUTL Schedule 13G/A use?

The percentage ownership is based on 266,141,286 Shares outstanding as of November 11, 2025, as stated in the filing and referenced to the issuer's 10-Q filed November 12, 2025.
AUTOLUS THERAPEUTICS PLC

NASDAQ:AUTL

AUTL Rankings

AUTL Latest News

AUTL Latest SEC Filings

AUTL Stock Data

415.18M
246.72M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United Kingdom
LONDON